$MRNA
Moderna, Inc. Stock $mrna

$mrna Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000168285219000023 Filed on May 09, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$13.08M	$16.03M	$29.04M
YoY Change	-54.65%	-44.82%	-4.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$28.50M	$27.30M	$16.30M
YoY Change	33.18%	67.48%
% of Gross Profit
Research & Development	$128.3M	$130.4M	$90.12M
YoY Change	22.8%	44.7%
% of Gross Profit
Depreciation & Amortization	$7.500M	$7.300M	$5.200M
YoY Change	27.12%	40.38%
% of Gross Profit
Operating Expenses	$156.8M	$157.7M	$106.4M
YoY Change	24.57%	48.13%	11.12%
Operating Profit	-$143.7M	-$141.6M	-$77.40M
YoY Change	48.13%	82.99%	18.24%
Interest Expense	$8.600M	$9.400M	$5.200M
YoY Change	34.38%	80.77%
% of Operating Profit
Other Income/Expense, Net	-$1.877M	-$1.931M	-$183.0K
YoY Change	-1197.66%	955.19%
Pretax Income	-$135.3M	-$132.6M	-$72.38M
YoY Change	49.56%	83.21%
Income Tax	-$324.0K	-$24.00K	$0.00
% Of Pretax Income
Net Earnings	-$134.9M	-$132.6M	-$72.38M
YoY Change	48.94%	83.18%
Net Earnings / Revenue	-1031.41%	-827.31%	-249.24%
Basic Earnings Per Share
Diluted Earnings Per Share	-$409.8K	-$403.3K	-$223.2K
COMMON SHARES
Basic Shares Outstanding	329.0M shares	329.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.070B	$1.109B
YoY Change	-4.0%
Cash & Equivalents	$151.6M	$502.9M	$90.48M
Short-Term Investments	$918.7M	$606.0M
Other Short-Term Assets	$9.000M	$8.000M
YoY Change	-68.97%
Inventory
Prepaid Expenses	$9.138M	$7.895M
Receivables	$3.498M	$8.948M
Other Receivables	$13.00M	$17.00M
Total Short-Term Assets	$1.097B	$1.141B
YoY Change	-5.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$208.5M	$209.5M
YoY Change	3.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$365.0M	$438.0M
YoY Change	64.41%
Other Assets	$2.558M	$2.438M
YoY Change	-82.95%
Total Long-Term Assets	$587.9M	$879.1M
YoY Change	33.91%
TOTAL ASSETS
Total Short-Term Assets	$1.097B	$1.141B
Total Long-Term Assets	$587.9M	$879.1M
Total Assets	$1.685B	$2.020B
YoY Change	5.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$29.61M	$38.51M
YoY Change	5.75%
Accrued Expenses	$44.59M	$42.18M
YoY Change	-7.11%
Deferred Revenue	$83.40M	$81.78M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$162.0M	$159.2M
YoY Change	-19.01%
LONG-TERM LIABILITIES
Long-Term Debt	$34.00M	$33.00M
YoY Change	25.93%
Other Long-Term Liabilities	$188.0K	$213.0K
YoY Change	-99.92%
Total Long-Term Liabilities	$188.0K	$213.0K
YoY Change	-99.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$162.0M	$159.2M
Total Long-Term Liabilities	$188.0K	$213.0K
Total Liabilities	$346.7M	$360.2M
YoY Change	-23.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.246B	-$982.4M
YoY Change
Common Stock	$33.00K	$33.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.335B	$1.442B	-$613.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.685B	$2.020B
YoY Change	5.2%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$134.9M	-$132.6M	-$72.38M
YoY Change	48.94%	83.18%
Depreciation, Depletion And Amortization	$7.500M	$7.300M	$5.200M
YoY Change	27.12%	40.38%
Cash From Operating Activities	-$108.6M	-$144.3M	-$111.4M
YoY Change	125.31%	29.52%
INVESTING ACTIVITIES
Capital Expenditures	-$10.60M	$7.595M	$31.91M
YoY Change	-68.91%	-76.2%
Acquisitions
YoY Change
Other Investing Activities	-$236.3M	-$4.200M	-$451.8M
YoY Change	-1154.91%	-99.07%
Cash From Investing Activities	-$246.9M	-$11.76M	-$483.7M
YoY Change	2028.45%	-97.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.200M	$293.0K	$550.0M
YoY Change	-96.2%	-99.95%
NET CHANGE
Cash From Operating Activities	-108.6M	-$144.3M	-$111.4M
Cash From Investing Activities	-246.9M	-$11.76M	-$483.7M
Cash From Financing Activities	4.200M	$293.0K	$550.0M
Net Change In Cash	-351.3M	-$155.7M	-$45.09M
YoY Change	-794.27%	245.35%
FREE CASH FLOW
Cash From Operating Activities	-$108.6M	-$144.3M	-$111.4M
Capital Expenditures	-$10.60M	$7.595M	$31.91M
Free Cash Flow	-$98.00M	-$151.9M	-$143.3M
YoY Change	595.04%	5.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001682852
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	329003270	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Moderna, Inc.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q4	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	21578000	USD
CY2019Q1	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	22850000	USD
CY2018Q4	mrna	Accrued In Licenses Current AccruedInLicensesCurrent	22000000	USD
CY2019Q1	mrna	Accrued In Licenses Current AccruedInLicensesCurrent	0	USD
CY2018Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	12089000	USD
CY2019Q1	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	7756000	USD
CY2019Q1	mrna	Contract With Customer Asset Decrease During Period ContractWithCustomerAssetDecreaseDuringPeriod	3747000	USD
CY2019Q1	mrna	Contract With Customer Asset Increase During Period ContractWithCustomerAssetIncreaseDuringPeriod	2735000	USD
CY2019Q1	mrna	Contract With Customer Liability Decrease During Period ContractWithCustomerLiabilityDecreaseDuringPeriod	13582000	USD
CY2019Q1	mrna	Contract With Customer Liability Increase During Period ContractWithCustomerLiabilityIncreaseDuringPeriod	1137000	USD
CY2018Q1	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	152000	USD
CY2019Q1	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	550000	USD
CY2018Q4	mrna	Lease Financing Obligation LeaseFinancingObligation	33489000	USD
CY2019Q1	mrna	Lease Financing Obligation LeaseFinancingObligation	33384000	USD
CY2018Q1	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	9889000	USD
CY2019Q1	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	10089000	USD
CY2018Q1	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	9889000	USD
CY2019Q1	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	10089000	USD
CY2018Q1	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	1285000	USD
CY2019Q1	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	105000	USD
CY2018Q1	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	1727000	USD
CY2019Q1	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	0	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1320000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	591000	USD
CY2019Q1	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	4.05
CY2019Q1	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	5.62
CY2019Q1	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue	8.48
CY2018Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	6.59
CY2019Q1	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	6.99
CY2019Q1	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue	9.55
CY2018Q1	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2019Q1	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	796000	USD
CY2018Q4	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	10089000	USD
CY2019Q1	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	11336000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31210000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	38509000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11686000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5646000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8948000	USD
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	899000	USD
CY2019Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	965000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	79073000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42183000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	64456000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	71735000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2538155000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2556709000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11851000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18497000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11851000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18497000	USD
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	305141893	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54433161	shares
CY2018Q4	us-gaap	Assets Assets	1962149000	USD
CY2019Q1	us-gaap	Assets Assets	1806207000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1563006000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	1140827000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1037372000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1042516000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	173369000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	436829000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	172990000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	437659000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	1036053000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	1043649000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	864003000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	605687000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	863063000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	605990000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	863063000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	605990000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	172990000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	437659000	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	28527000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14127000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90479000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	658364000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	502934000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147608000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102514000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	670491000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	514757000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45094000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-155734000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	328798904	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	328853340	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	328798904	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	328853340	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74369000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-130746000	USD
CY2018Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4612000	USD
CY2019Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3600000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	240924000	USD
CY2019Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	228479000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	109056000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	73958000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	81775000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	165352000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	156862000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	161911000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	13582000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	28529000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	27984000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	82800000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	135800000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	400000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	200000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	25	security
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	32	security
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10006000	USD
CY2019Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	10556000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5153000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5200000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7300000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7328000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.16
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23406000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11577000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	253100000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M
CY2018Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-19000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16317000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27283000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-72376000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-132681000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1467000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1731000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3876000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6040000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	66000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-37031000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-32557000	USD
CY2018Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	6193000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15604000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	183000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	484000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2241000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3313000	USD
CY2018Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	7909000	USD
CY2019Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	6061000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5209000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	10972000	USD
CY2018Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	83000	USD
CY2019Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1005000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	431908000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	360174000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1962149000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1806207000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	222803000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	159159000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	549995000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-48000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-483704000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11759000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-111385000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-143927000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-72376000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-132657000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75857000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-132657000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	106441000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	157858000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-77402000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-141833000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	246506000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	20498000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	23455000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	24105000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	22874000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	140384000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	15190000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5200000	USD
CY2019Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4800000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2644000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2438000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1993000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1911000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-6000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-3000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1999000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1908000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	540000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3464000	USD
CY2019Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4509000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	213000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-183000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1820000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10517000	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	660239000	USD
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	429517000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31909000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7595000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28399000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	25292000	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10401000	USD
CY2019Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7895000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	549531000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2018Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	189814000	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	403940000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	18630000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	21413000	USD
CY2018Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	22000	USD
CY2019Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	57000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	276433000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	285195000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	211977000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	213460000	USD
CY2019Q1	us-gaap	Property Subject To Or Available For Operating Lease Number Of Units PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits	2	campus
CY2018Q1	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	3481000	USD
CY2019Q1	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	90124000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	130575000	USD
CY2018Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	237000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	595000	USD
CY2019Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2018Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11798000	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11532000	USD
CY2019Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11823000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1006627000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1111300000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-978643000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16025000	USD
CY2019Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	279500000	USD
CY2018Q1	us-gaap	Revenues Revenues	29039000	USD
CY2019Q1	us-gaap	Revenues Revenues	16025000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11851000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	18497000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	72400000.0	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	24769502	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.54
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2987612	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5443286	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.16
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	220434000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	412480000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	50821132	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	53271281	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.16
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.92
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	119876000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	28501493	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.73
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.62
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.29
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.59
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	292602000	USD
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M15D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y0M
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5525	shares
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	152000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	22000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	100000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	57000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-551365000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-613709000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1530241000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1446033000	USD
CY2018Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	509352795	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65430835	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	328809986	shares

Files In Submission

Name	View Source	Status
0001682852-19-000023-index-headers.html	Edgar Link	pending
0001682852-19-000023-index.html	Edgar Link	pending
0001682852-19-000023.txt	Edgar Link	pending
0001682852-19-000023-xbrl.zip	Edgar Link	pending
a0001193125183449821_image43.jpg	Edgar Link	pending
a0001193125183449821_image44.jpg	Edgar Link	pending
a0001193125183449821_image45.jpg	Edgar Link	pending
a0001193125183449821_image46.jpg	Edgar Link	pending
a190418gsd1acellimage.jpg	Edgar Link	pending
a190419gsd1a1.jpg	Edgar Link	pending
a190419gsd1a2.jpg	Edgar Link	pending
a190419gsd1a3.jpg	Edgar Link	pending
a190425cellmapa02.jpg	Edgar Link	pending
a190430rsvmrna1172andmrna177.jpg	Edgar Link	pending
a190502pipeline.jpg	Edgar Link	pending
exhibit101amendedandrestat.htm	Edgar Link	pending
exhibit3113312019.htm	Edgar Link	pending
exhibit3123312019.htm	Edgar Link	pending
exhibit3213312019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
moderna10-q3312019.htm	Edgar Link	pending
modernalogo.jpg	Edgar Link	pending
mrna-20190331.xml	Edgar Link	completed
mrna-20190331.xsd	Edgar Link	pending
mrna-20190331_cal.xml	Edgar Link	unprocessable
mrna-20190331_def.xml	Edgar Link	unprocessable
mrna-20190331_lab.xml	Edgar Link	unprocessable
mrna-20190331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rsv.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNA
Moderna, Inc. Stock $mrna

2019 Q2 Form 10-Q Financial Statement

#000168285219000023 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA Moderna, Inc. Stock $mrna

2019 Q2 Form 10-Q Financial Statement

#000168285219000023 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA
Moderna, Inc. Stock $mrna